{"generic":"Elvitegravir","drugs":["Elvitegravir","Vitekta"],"mono":{"0":{"id":"930882-s-0","title":"Generic Names","mono":"Elvitegravir"},"1":{"id":"930882-s-1","title":"Dosing and Indications","sub":[{"id":"930882-s-1-4","title":"Adult Dosing","mono":"<ul><li>must be administered only in combination with the recommended protease inhibitors, ritonavir, and another antiretroviral agent(s)<\/li><li><b>HIV infection:<\/b> 85 mg ORALLY once daily coadministered with atazanavir 300 mg and ritonavir 100 mg ORALLY once daily; must also be given with another additional antiretroviral agent(s)<\/li><li><b>HIV infection:<\/b> 85 mg ORALLY once daily coadministered with lopinavir 400 mg and ritonavir 100 mg ORALLY which are given twice daily; must also be given with another additional antiretroviral agent(s)<\/li><li><b>HIV infection:<\/b> 150 mg ORALLY once daily coadministered with darunavir 600 mg and ritonavir 100 mg ORALLY which are given twice daily; must be given with another additional antiretroviral agent(s)<\/li><li><b>HIV infection:<\/b> 150 mg ORALLY once daily coadministered with fosamprenavir 700 mg and ritonavir 100 mg ORALLY which are given twice daily; must be given with another additional antiretroviral agent(s)<\/li><li><b>HIV infection:<\/b> 150 mg ORALLY once daily coadministered with tipranavir 500 mg and ritonavir 200 mg ORALLY which are given twice daily; must be given with another additional antiretroviral agent(s)<\/li><\/ul>"},{"id":"930882-s-1-5","title":"Pediatric Dosing","mono":"safety and efficacy have not been established in pediatric patients "},{"id":"930882-s-1-6","title":"Dose Adjustments","mono":"<ul><li><b>renal impairment:<\/b> No adjustment required<\/li><li><b>hepatic impairment:<\/b> No adjustment required in mild (Child-Pugh class A) or moderate (Child-Pugh class B) impairment; use not recommended in severe impairment (Child-Pugh class C)<\/li><\/ul>"},{"id":"930882-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><br\/>HIV infection<br\/>"}]},"3":{"id":"930882-s-3","title":"Contraindications\/Warnings","sub":[{"id":"930882-s-3-9","title":"Contraindications","mono":"specific contraindications have not been determined <br\/>"},{"id":"930882-s-3-10","title":"Precautions","mono":"<ul><li>Hepatic:<\/li><li>-- use is not recommended in severe hepatic impairment (Child-Pugh class C)<\/li><li>Immunologic:<\/li><li>-- immune reconstitution syndrome may occur, leading to an inflammatory response in patients with indolent or residual opportunistic infections<\/li><li>-- autoimmune disorders (eg, Graves disease, polymyositis, Guillain-Barre syndrome) have been reported in the setting of immune reconstitution and may occur many months after initiation of therapy<\/li><li>Reproductive:<\/li><li>-- breastfeeding; avoid risk of postnatal HIV transmission<\/li><li>Concomitant use:<\/li><li>-- avoid use with antimycobacterials (ie, rifampin or rifapentine)<\/li><li>-- avoid use with hepatitis C virus (HCV) protease inhibitors (ie, telaprevir or boceprevir)<\/li><li>-- avoid use with non-nucleoside reverse transcriptase inhibitors (ie, efavirenz or nevirapine)<\/li><li>-- avoid use with St. John's wort<\/li><li>-- avoid use with medications that contain elvitegravir<\/li><li>-- avoid use with a protease inhibitor and cobicistat<\/li><\/ul>"},{"id":"930882-s-3-11","title":"Pregnancy Category","mono":"<ul><li>B (FDA)<\/li><li>B2 (AUS)<\/li><\/ul>"},{"id":"930882-s-3-12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"4":{"id":"930882-s-4","title":"Drug Interactions","sub":[{"id":"930882-s-4-13","title":"Contraindicated","mono":"<ul><li>Rifampin (theoretical)<\/li><li>St John's Wort (theoretical)<\/li><\/ul>"},{"id":"930882-s-4-14","title":"Major","mono":"<ul><li>Aluminum Carbonate, Basic (established)<\/li><li>Aluminum Hydroxide (established)<\/li><li>Aluminum Phosphate (established)<\/li><li>Amobarbital (theoretical)<\/li><li>Aprepitant (theoretical)<\/li><li>Aprobarbital (theoretical)<\/li><li>Armodafinil (theoretical)<\/li><li>Bosentan (theoretical)<\/li><li>Butabarbital (theoretical)<\/li><li>Butalbital (theoretical)<\/li><li>Calcium Carbonate (established)<\/li><li>Carbamazepine (theoretical)<\/li><li>Ceritinib (theoretical)<\/li><li>Clobazam (theoretical)<\/li><li>Crizotinib (theoretical)<\/li><li>Dabrafenib (theoretical)<\/li><li>Darunavir (theoretical)<\/li><li>Dasabuvir (theoretical)<\/li><li>Dexamethasone (theoretical)<\/li><li>Dihydroxyaluminum Aminoacetate (established)<\/li><li>Dihydroxyaluminum Sodium Carbonate (established)<\/li><li>Efavirenz (theoretical)<\/li><li>Enzalutamide (theoretical)<\/li><li>Eslicarbazepine Acetate (theoretical)<\/li><li>Ethosuximide (theoretical)<\/li><li>Etravirine (theoretical)<\/li><li>Fosaprepitant (theoretical)<\/li><li>Fosphenytoin (theoretical)<\/li><li>Idelalisib (theoretical)<\/li><li>Itraconazole (theoretical)<\/li><li>Ketoconazole (established)<\/li><li>Magaldrate (established)<\/li><li>Magnesium Carbonate (established)<\/li><li>Magnesium Hydroxide (established)<\/li><li>Magnesium Oxide (established)<\/li><li>Magnesium Trisilicate (established)<\/li><li>Mephobarbital (theoretical)<\/li><li>Methohexital (theoretical)<\/li><li>Mitotane (theoretical)<\/li><li>Modafinil (theoretical)<\/li><li>Nafcillin (theoretical)<\/li><li>Nevirapine (theoretical)<\/li><li>Nilotinib (theoretical)<\/li><li>Ombitasvir (theoretical)<\/li><li>Oxcarbazepine (theoretical)<\/li><li>Paritaprevir (theoretical)<\/li><li>Pentobarbital (theoretical)<\/li><li>Phenobarbital (theoretical)<\/li><li>Phenytoin (theoretical)<\/li><li>Pioglitazone (theoretical)<\/li><li>Piperaquine (theoretical)<\/li><li>Prednisolone (theoretical)<\/li><li>Prednisone (theoretical)<\/li><li>Primidone (theoretical)<\/li><li>Rifabutin (theoretical)<\/li><li>Rifapentine (theoretical)<\/li><li>Rufinamide (theoretical)<\/li><li>Secobarbital (theoretical)<\/li><li>Siltuximab (theoretical)<\/li><li>Sodium Bicarbonate (established)<\/li><li>Thiopental (theoretical)<\/li><li>Topiramate (theoretical)<\/li><li>Vemurafenib (theoretical)<\/li><li>Voriconazole (theoretical)<\/li><li>Warfarin (theoretical)<\/li><\/ul>"}]},"5":{"id":"930882-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Endocrine metabolic:<\/b>Hypercholesterolemia (Grade 3 or 4, 5%), Hyperglycemia (Grade 3 or 4, 5%)<\/li><li><b>Gastrointestinal:<\/b>Diarrhea (7%), Nausea (4%)<\/li><\/ul><b>Serious<\/b><ul><li><b>Endocrine metabolic:<\/b>Gamma-glutamyl transferase raised (Grade 3 or 4, 3%), Hypertriglyceridemia (Grade 3 or 4, 5%)<\/li><li><b>Gastrointestinal:<\/b>High lipase level in serum (Grade 3 or 4, 14%), Serum amylase raised (Grade 3 or 4, 6%)<\/li><li><b>Hematologic:<\/b>Neutropenia (Grade 3 or 4, 3%)<\/li><li><b>Hepatic:<\/b>ALT\/SGPT level raised (Grade 3 or 4, 2%), AST\/SGOT level raised (Grade 3 or 4, 2%), Serum bilirubin raised (Grade 3 or 4, 6%)<\/li><li><b>Immunologic:<\/b>Immune reconstitution syndrome<\/li><li><b>Musculoskeletal:<\/b>Increased creatine kinase level (Grade 3 or 4, 6%)<\/li><li><b>Psychiatric:<\/b>At risk for suicide, Suicidal thoughts<\/li><li><b>Renal:<\/b>Hematuria (Grade 3 or 4, 6%)<\/li><\/ul>"},"6":{"id":"930882-s-6","title":"Drug Name Info","sub":{"0":{"id":"930882-s-6-17","title":"US Trade Names","mono":"Vitekta<br\/>"},"2":{"id":"930882-s-6-19","title":"Class","mono":"<ul><li>Antiretroviral Agent<\/li><li>Integrase Inhibitor<\/li><\/ul>"},"3":{"id":"930882-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"930882-s-6-21","title":"Generic Availability","mono":"No<br\/>"}}},"7":{"id":"930882-s-7","title":"Mechanism Of Action","mono":"Elvitegravir is an HIV-1 integrase strand transfer inhibitor. By inhibiting HIV-1 integrase, the HIV virus is unable to integrate viral DNA into the host DNA for viral replication. Elvitegravir does not inhibit human topoisomerases I or II.<br\/>"},"8":{"id":"930882-s-8","title":"Pharmacokinetics","sub":[{"id":"930882-s-8-23","title":"Absorption","mono":"Tmax, oral: 4 hours <br\/>"},{"id":"930882-s-8-24","title":"Distribution","mono":"Protein binding: 98% to 99% <br\/>"},{"id":"930882-s-8-25","title":"Metabolism","mono":"<ul><li>Hepatic: primary route via CYP3A and UGT1A1\/3<\/li><li>Aromatic and aliphatic hydroxylated or glucuronidated metabolites: inactive<\/li><li>inducer of CYP2C9 (modest)<\/li><li>substrate of CYP3A<\/li><\/ul>"},{"id":"930882-s-8-26","title":"Excretion","mono":"<ul><li>Fecal: 94.8% unchanged<\/li><li>Renal: 6.7% as metabolites<\/li><li>Dialyzable: Unlikely (hemodialysis); Unlikely (peritoneal dialysis)<\/li><\/ul>"},{"id":"930882-s-8-27","title":"Elimination Half Life","mono":"8.7 hours <br\/>"}]},"9":{"id":"930882-s-9","title":"Administration","mono":"<b>General Information<\/b><br\/><ul><li>administer once daily with food<\/li><li>must be coadministered with a ritonavir-boosted protease inhibitor; if using with protease inhibitor that is dosed twice daily, administer elvitegravir with the first dose<\/li><li>separate antacid use and elvitegravir by at least 2 hours<\/li><\/ul>"},"10":{"id":"930882-s-10","title":"Monitoring","mono":"<ul><li>Viral load: at baseline and with modification of antiretroviral (ARV) treatment, at 2 to 8 weeks; then every 4 to 8 weeks until values are below the limit of detection (less than 200 copies\/mL), then every 3 to 4 months; monitoring may be extended to every 6 months for patients who are immunologically stable, adherent, and with suppressed viral loads for more than 2 years<\/li><li>CD4 cell counts: at baseline and with modification of ARV treatment, then every 3 to 6 months during the at least the first 2 years of treatment and if the CD4 counts are below 300 cells\/mm(3) or viremia develops; after 2 years monitoring may be extended to every 12 months for patients who are clinically stable with suppressed viral loads<\/li><li>Hepatitis B screening: baseline and with modification of ARV treatment; may repeat screening if hepatitis B surface antigen or antibody are negative at baseline.<\/li><li>ALT, AST, and total bilirubin; at baseline and with modification of ARV treatment, at 2 to 8 weeks, then every 3 to 6 months<\/li><li>Basic chemistry, including serum sodium, potassium, bicarbonate, chloride, BUN, and creatinine; at baseline and with modification of ARV treatment, at 2 to 8 weeks, then every 3 to 6 months<\/li><li>CBC with a differential; at baseline and with modification of ARV treatment, then every 3 to 6 months<\/li><li>Fasting blood glucose or HbA1c; at baseline and with modification of ARV treatment, then every 3 to 6 months with abnormal values or 12 months with normal values<\/li><li>Fasting lipid profile; at baseline and with modification of ARV treatment, at 2 to 8 weeks, then every 6 to 12 months<\/li><li>Urinalysis; at baseline or modification of ARV treatment, then annually<\/li><\/ul>"},"11":{"id":"930882-s-11","title":"How Supplied","mono":"<b>Vitekta<\/b><br\/>Oral Tablet: 85 MG, 150 MG<br\/>"},"13":{"id":"930882-s-13","title":"Clinical Teaching","mono":"<ul><li>Advise patient to report symptoms of inflammation or infection.<\/li><li>Side effects may include diarrhea, nausea, or headaches.<\/li><li>Instruct patient to take drug with food.<\/li><\/ul>"}}}